C. Colin, L. Padovani, C. Chappé, S. Mercurio, D. Scavarda et al., Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution, Neuropathology and Applied Neurobiology, vol.22, issue.6, pp.693-705, 2013.
DOI : 10.1111/nan.12013

R. J. Packer, R. Jakati, M. Horn, B. Rood, G. Vezina et al., Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan, Pediatric Blood & Cancer, vol.32, issue.7, pp.791-795, 2009.
DOI : 10.1002/pbc.21935

E. Hwang, R. Jakati, L. B. Kilburn, M. Horn, G. Vezina et al., Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas, Pediatric Blood & Cancer, vol.54, issue.5, pp.776-782, 2013.
DOI : 10.1002/pbc.24297

M. L. Couec, N. André, E. Thebaud, O. Minckes, X. Rialland et al., Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends, Pediatric Blood & Cancer, vol.44, issue.1, pp.34-38, 2012.
DOI : 10.1002/pbc.24066

S. Gururangan, J. Fanguraso, T. Y. Poussaint, R. E. Mclendon, A. Onar-thomas et al., Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study, Neuro-Oncology, vol.16, issue.2, pp.310-317, 2014.
DOI : 10.1093/neuonc/not154

R. J. Packer, Brain Tumors in Children, Archives of Neurology, vol.56, issue.4, pp.421-425, 1999.
DOI : 10.1001/archneur.56.4.421

L. Lafay-cousin, S. Holm, I. Qaddoumi, G. Nicolin, U. Bartels et al., Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction, Cancer, vol.105, issue.12, pp.2636-2642, 2005.
DOI : 10.1002/cncr.21091

E. Bouffet, R. Jakacki, S. Goldman, D. Hargrave, C. Hawkins et al., Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma, Journal of Clinical Oncology, vol.30, issue.12, pp.1358-1363, 2012.
DOI : 10.1200/JCO.2011.34.5843

A. M. Capellano, A. S. Petrilli, N. S. Da-silva, F. A. Silva, P. M. Paiva et al., Single agent vinorelbine in pediatric patients with progressive optic pathway glioma, Journal of Neuro-Oncology, vol.46, issue.12, pp.105-112, 2015.
DOI : 10.1007/s11060-014-1652-6

N. André, S. Abed, D. Orbach, C. A. Alla, L. Padovani et al., Pilot study of a pediatric metronomic 4-drug regimen, Oncotarget, vol.2, issue.12, pp.960-965, 2011.
DOI : 10.18632/oncotarget.358

N. André, M. Carré, and E. Pasquier, Metronomics: towards personalized chemotherapy?, Nature Reviews Clinical Oncology, vol.41, issue.7, pp.413-431, 2014.
DOI : 10.1016/j.ejca.2012.11.029

N. J. Robison, F. Campigotto, S. N. Chi, P. E. Manley, C. D. Turner et al., A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer, Pediatric Blood & Cancer, vol.82, issue.4, pp.636-642, 2014.
DOI : 10.1002/pbc.24794

D. Zapletalova, N. André, L. Deak, M. Kyr, V. Bajciova et al., Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience, Oncology, vol.82, issue.5, pp.249-260, 2012.
DOI : 10.1159/000336483

N. André, S. Cointe, V. Barlogis, L. Arnaud, R. Lacroix et al., Maintenance chemotherapy in children with aLL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect, Oncotarget, vol.6, issue.26, pp.23008-23014, 2015.
DOI : 10.18632/oncotarget.3984